Ashley Lowe, APRN
Primary Care · San Diego, CANPI 1770024093
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,128 of the $18,540 with a category attached, or 65.4%. 37 manufacturers reported payments, led by Bayer at 34.2% of the total. 2025 is the largest year on record at $9,072, more than ten times the $66 reported in 2022. Among primary care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 326 payments — averaging $56.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$6K
- Johnson & Johnson$2K
- Dendreon Pharmaceuticals LLC$2K
- Axonics, Inc.$2K
- Astellas Pharma US Inc$670
- Sun Pharmaceutical Industries Inc.$443
- plus $5K from 31 others
What the payments were for
- Consulting fees$3,68020%
- Travel & lodging$2,26512%
- Food & beverage$12,12865%
- Education$4673%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 38 | $6,335 |
| Johnson & Johnson | 45 | $2,156 |
| Dendreon Pharmaceuticals LLC | 34 | $1,877 |
| Axonics, Inc. | 15 | $1,838 |
| Astellas Pharma US Inc | 13 | $670 |
| Sun Pharmaceutical Industries Inc. | 22 | $443 |
| Myriad Genetic Laboratories, Inc. | 12 | $433 |
| Sumitomo Pharma America, Inc. | 16 | $421 |
| Pfizer | 18 | $418 |
| Blue Earth Diagnostics | 9 | $377 |
| Procept Biorobotics Corporation | 3 | $347 |
| Progenics Pharmaceuticals, Inc. | 18 | $339 |
| Merck | 7 | $310 |
| AstraZeneca | 11 | $270 |
| Urogen Pharma, Inc. | 5 | $228 |
| EDAP Technomed Inc | 2 | $222 |
| AbbVie | 8 | $220 |
| Teleflex LLC | 3 | $203 |
| Endo Pharmaceuticals Inc. | 1 | $164 |
| Novartis | 5 | $146 |
| Janssen Scientific Affairs, LLC | 2 | $143 |
| Accord Healthcare, Inc. | 7 | $143 |
| Immunitybio, Inc. | 6 | $123 |
| Verity Pharmaceuticals Inc. | 4 | $100 |
| Convatec Inc. | 4 | $91 |
| Boston Scientific | 1 | $89 |
| Antares Pharma, Inc. | 4 | $77 |
| SRS Medical Systems, Inc. | 1 | $63 |
| 180 Medical, Inc. | 2 | $51 |
| Caris MPI, Inc. | 2 | $48 |
| Foundation Medicine, Inc. | 2 | $44 |
| Telix Pharmaceuticals | 1 | $30 |
| Tempus AI, Inc | 1 | $29 |
| Angiodynamics, Inc. | 1 | $28 |
| Koelis Inc. | 1 | $26 |
| ABC Home Medical Supply, Inc. | 1 | $21 |
| Halozyme Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,540 in reported general payments places this provider in the 95th percentile of 706 primary care providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 60 | $802,086 |
| ErleadaApalutamide | 45 | $630,517 |
| NubeqaDarolutamide | 24 | $298,492 |
| OrgovyxRelugolix | 75 | $189,252 |
| Abiraterone Acetate | 19 | $69,244 |
| GemtesaVibegron | 33 | $22,728 |
| MyrbetriqMirabegron | 33 | $22,216 |
| Methenamine Hippurate | 16 | $1,408 |
| Potassium Citrate ErPotassium Citrate | 12 | $1,312 |
| Tamsulosin Hcl | 94 | $1,183 |
| Testosterone | 15 | $1,041 |
| Estradiol | 22 | $912 |
| Oxybutynin Chloride ErOxybutynin Chloride | 36 | $883 |
| Cephalexin | 27 | $598 |
| Finasteride | 41 | $478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $670 | $824,30393 claims |
| Johnson & JohnsonErleada | $2,156 | $630,51745 claims |
| BayerNubeqa | $6,335 | $298,49224 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $421 | $211,979108 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $143 | $69,24419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 706 primary care providers in California.
Other primary care in San Diego
- Kathryn CooperSan Diego$31K
- Pailai KingSan Diego$15K
- Leslie FletcherTorrance$1.8M
- Hamideh PourzandLos Angeles$103K
- Veronica RamirezSacramento$83K
- Tyson FieldstedBakersfield$65K
- Shalaine Corbillala Mesa$22K
- Paula StoddardHanford$22K
- Vanessa LeeLong Beach$16K
- Lynda TranHuntington Beach$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.